The global market for Noninvasive Delivery Vaccine was estimated to be worth US$ 2670 million in 2023 and is forecast to a readjusted size of US$ 3909.1 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030

Noninvasive Delivery Vaccine - Market

Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.

The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Noninvasive Delivery Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Noninvasive Delivery Vaccine by region & country, by Type, and by Application.

The Noninvasive Delivery Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Delivery Vaccine.

Market Segmentation

Scope of Noninvasive Delivery Vaccine - Market Report

Report Metric	Details
Report Name	Noninvasive Delivery Vaccine - Market
Forecasted market size in 2030	US$ 3909.1 million
CAGR	5.6%
Forecasted years	2024 - 2030
Segment by Type:	Oral Vaccine Nasal Spray Vaccine
Segment by Application	Public Private
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals, AstraZeneca, Cipla, BCHT
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Noninvasive Delivery Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Noninvasive Delivery Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Noninvasive Delivery Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Noninvasive Delivery Vaccine - Market size in 2030?

Ans: The Noninvasive Delivery Vaccine - Market size in 2030 will be US$ 3909.1 million.

Who are the main players in the Noninvasive Delivery Vaccine - Market report?

Ans: The main players in the Noninvasive Delivery Vaccine - Market are Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals, AstraZeneca, Cipla, BCHT

What are the Application segmentation covered in the Noninvasive Delivery Vaccine - Market report?

Ans: The Applications covered in the Noninvasive Delivery Vaccine - Market report are Public, Private

What are the Type segmentation covered in the Noninvasive Delivery Vaccine - Market report?

Ans: The Types covered in the Noninvasive Delivery Vaccine - Market report are Oral Vaccine, Nasal Spray Vaccine

1 Market Overview

1.1 Noninvasive Delivery Vaccine Product Introduction

1.2 Global Noninvasive Delivery Vaccine Market Size Forecast

1.2.1 Global Noninvasive Delivery Vaccine Sales Value (2019-2030)

1.2.2 Global Noninvasive Delivery Vaccine Sales Volume (2019-2030)

1.2.3 Global Noninvasive Delivery Vaccine Sales Price (2019-2030)

1.3 Noninvasive Delivery Vaccine Market Trends & Drivers

1.3.1 Noninvasive Delivery Vaccine Industry Trends

1.3.2 Noninvasive Delivery Vaccine Market Drivers & Opportunity

1.3.3 Noninvasive Delivery Vaccine Market Challenges

1.3.4 Noninvasive Delivery Vaccine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Noninvasive Delivery Vaccine Players Revenue Ranking (2023)

2.2 Global Noninvasive Delivery Vaccine Revenue by Company (2019-2024)

2.3 Global Noninvasive Delivery Vaccine Players Sales Volume Ranking (2023)

2.4 Global Noninvasive Delivery Vaccine Sales Volume by Company Players (2019-2024)

2.5 Global Noninvasive Delivery Vaccine Average Price by Company (2019-2024)

2.6 Key Manufacturers Noninvasive Delivery Vaccine Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Noninvasive Delivery Vaccine Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Noninvasive Delivery Vaccine

2.9 Noninvasive Delivery Vaccine Market Competitive Analysis

2.9.1 Noninvasive Delivery Vaccine Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Noninvasive Delivery Vaccine Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Delivery Vaccine as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Oral Vaccine

3.1.2 Nasal Spray Vaccine

3.2 Global Noninvasive Delivery Vaccine Sales Value by Type

3.2.1 Global Noninvasive Delivery Vaccine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Noninvasive Delivery Vaccine Sales Value, by Type (2019-2030)

3.2.3 Global Noninvasive Delivery Vaccine Sales Value, by Type (%) (2019-2030)

3.3 Global Noninvasive Delivery Vaccine Sales Volume by Type

3.3.1 Global Noninvasive Delivery Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Noninvasive Delivery Vaccine Sales Volume, by Type (2019-2030)

3.3.3 Global Noninvasive Delivery Vaccine Sales Volume, by Type (%) (2019-2030)

3.4 Global Noninvasive Delivery Vaccine Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Public

4.1.2 Private

4.2 Global Noninvasive Delivery Vaccine Sales Value by Application

4.2.1 Global Noninvasive Delivery Vaccine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Noninvasive Delivery Vaccine Sales Value, by Application (2019-2030)

4.2.3 Global Noninvasive Delivery Vaccine Sales Value, by Application (%) (2019-2030)

4.3 Global Noninvasive Delivery Vaccine Sales Volume by Application

4.3.1 Global Noninvasive Delivery Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Noninvasive Delivery Vaccine Sales Volume, by Application (2019-2030)

4.3.3 Global Noninvasive Delivery Vaccine Sales Volume, by Application (%) (2019-2030)

4.4 Global Noninvasive Delivery Vaccine Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Noninvasive Delivery Vaccine Sales Value by Region

5.1.1 Global Noninvasive Delivery Vaccine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Noninvasive Delivery Vaccine Sales Value by Region (2019-2024)

5.1.3 Global Noninvasive Delivery Vaccine Sales Value by Region (2025-2030)

5.1.4 Global Noninvasive Delivery Vaccine Sales Value by Region (%), (2019-2030)

5.2 Global Noninvasive Delivery Vaccine Sales Volume by Region

5.2.1 Global Noninvasive Delivery Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Noninvasive Delivery Vaccine Sales Volume by Region (2019-2024)

5.2.3 Global Noninvasive Delivery Vaccine Sales Volume by Region (2025-2030)

5.2.4 Global Noninvasive Delivery Vaccine Sales Volume by Region (%), (2019-2030)

5.3 Global Noninvasive Delivery Vaccine Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Noninvasive Delivery Vaccine Sales Value, 2019-2030

5.4.2 North America Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Noninvasive Delivery Vaccine Sales Value, 2019-2030

5.5.2 Europe Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Noninvasive Delivery Vaccine Sales Value, 2019-2030

5.6.2 Asia Pacific Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Noninvasive Delivery Vaccine Sales Value, 2019-2030

5.7.2 South America Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Noninvasive Delivery Vaccine Sales Value, 2019-2030

5.8.2 Middle East & Africa Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Noninvasive Delivery Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Noninvasive Delivery Vaccine Sales Value

6.2.1 Key Countries/Regions Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.2.2 Key Countries/Regions Noninvasive Delivery Vaccine Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.3.2 United States Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.4.2 Europe Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.5.2 China Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.5.3 China Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.6.2 Japan Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.7.2 South Korea Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.8.2 Southeast Asia Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Noninvasive Delivery Vaccine Sales Value, 2019-2030

6.9.2 India Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

6.9.3 India Noninvasive Delivery Vaccine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck

7.1.1 Merck Company Information

7.1.2 Merck Introduction and Business Overview

7.1.3 Merck Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Merck Noninvasive Delivery Vaccine Product Offerings

7.1.5 Merck Recent Development

7.2 GSK

7.2.1 GSK Company Information

7.2.2 GSK Introduction and Business Overview

7.2.3 GSK Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.2.4 GSK Noninvasive Delivery Vaccine Product Offerings

7.2.5 GSK Recent Development

7.3 Sanofi

7.3.1 Sanofi Company Information

7.3.2 Sanofi Introduction and Business Overview

7.3.3 Sanofi Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Sanofi Noninvasive Delivery Vaccine Product Offerings

7.3.5 Sanofi Recent Development

7.4 Lanzhou Institute

7.4.1 Lanzhou Institute Company Information

7.4.2 Lanzhou Institute Introduction and Business Overview

7.4.3 Lanzhou Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Lanzhou Institute Noninvasive Delivery Vaccine Product Offerings

7.4.5 Lanzhou Institute Recent Development

7.5 Serum Institute

7.5.1 Serum Institute Company Information

7.5.2 Serum Institute Introduction and Business Overview

7.5.3 Serum Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Serum Institute Noninvasive Delivery Vaccine Product Offerings

7.5.5 Serum Institute Recent Development

7.6 Valneva

7.6.1 Valneva Company Information

7.6.2 Valneva Introduction and Business Overview

7.6.3 Valneva Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Valneva Noninvasive Delivery Vaccine Product Offerings

7.6.5 Valneva Recent Development

7.7 Shanghai United Cell

7.7.1 Shanghai United Cell Company Information

7.7.2 Shanghai United Cell Introduction and Business Overview

7.7.3 Shanghai United Cell Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Shanghai United Cell Noninvasive Delivery Vaccine Product Offerings

7.7.5 Shanghai United Cell Recent Development

7.8 Bibcol

7.8.1 Bibcol Company Information

7.8.2 Bibcol Introduction and Business Overview

7.8.3 Bibcol Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Bibcol Noninvasive Delivery Vaccine Product Offerings

7.8.5 Bibcol Recent Development

7.9 PaxVax

7.9.1 PaxVax Company Information

7.9.2 PaxVax Introduction and Business Overview

7.9.3 PaxVax Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.9.4 PaxVax Noninvasive Delivery Vaccine Product Offerings

7.9.5 PaxVax Recent Development

7.10 Vabiotech

7.10.1 Vabiotech Company Information

7.10.2 Vabiotech Introduction and Business Overview

7.10.3 Vabiotech Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Vabiotech Noninvasive Delivery Vaccine Product Offerings

7.10.5 Vabiotech Recent Development

7.11 Tiantan Biological

7.11.1 Tiantan Biological Company Information

7.11.2 Tiantan Biological Introduction and Business Overview

7.11.3 Tiantan Biological Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Tiantan Biological Noninvasive Delivery Vaccine Product Offerings

7.11.5 Tiantan Biological Recent Development

7.12 EuBiologics

7.12.1 EuBiologics Company Information

7.12.2 EuBiologics Introduction and Business Overview

7.12.3 EuBiologics Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.12.4 EuBiologics Noninvasive Delivery Vaccine Product Offerings

7.12.5 EuBiologics Recent Development

7.13 Panacea Biotec Ltd

7.13.1 Panacea Biotec Ltd Company Information

7.13.2 Panacea Biotec Ltd Introduction and Business Overview

7.13.3 Panacea Biotec Ltd Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Panacea Biotec Ltd Noninvasive Delivery Vaccine Product Offerings

7.13.5 Panacea Biotec Ltd Recent Development

7.14 Bio-Med

7.14.1 Bio-Med Company Information

7.14.2 Bio-Med Introduction and Business Overview

7.14.3 Bio-Med Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.14.4 Bio-Med Noninvasive Delivery Vaccine Product Offerings

7.14.5 Bio-Med Recent Development

7.15 Halfkin Bio-Pharmaceuticals

7.15.1 Halfkin Bio-Pharmaceuticals Company Information

7.15.2 Halfkin Bio-Pharmaceuticals Introduction and Business Overview

7.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Product Offerings

7.15.5 Halfkin Bio-Pharmaceuticals Recent Development

7.16 AstraZeneca

7.16.1 AstraZeneca Company Information

7.16.2 AstraZeneca Introduction and Business Overview

7.16.3 AstraZeneca Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.16.4 AstraZeneca Noninvasive Delivery Vaccine Product Offerings

7.16.5 AstraZeneca Recent Development

7.17 Cipla

7.17.1 Cipla Company Information

7.17.2 Cipla Introduction and Business Overview

7.17.3 Cipla Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.17.4 Cipla Noninvasive Delivery Vaccine Product Offerings

7.17.5 Cipla Recent Development

7.18 BCHT

7.18.1 BCHT Company Information

7.18.2 BCHT Introduction and Business Overview

7.18.3 BCHT Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.18.4 BCHT Noninvasive Delivery Vaccine Product Offerings

7.18.5 BCHT Recent Development

8 Industry Chain Analysis

8.1 Noninvasive Delivery Vaccine Industrial Chain

8.2 Noninvasive Delivery Vaccine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Noninvasive Delivery Vaccine Sales Model

8.5.2 Sales Channel

8.5.3 Noninvasive Delivery Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Halfkin Bio-Pharmaceuticals

List of Tables

Table 1. Noninvasive Delivery Vaccine Market Trends

Table 2. Noninvasive Delivery Vaccine Market Drivers & Opportunity

Table 3. Noninvasive Delivery Vaccine Market Challenges

Table 4. Noninvasive Delivery Vaccine Market Restraints

Table 5. Global Noninvasive Delivery Vaccine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Noninvasive Delivery Vaccine Revenue Market Share by Company (2019-2024)

Table 7. Global Noninvasive Delivery Vaccine Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Noninvasive Delivery Vaccine Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Noninvasive Delivery Vaccine Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Noninvasive Delivery Vaccine Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Noninvasive Delivery Vaccine Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Noninvasive Delivery Vaccine

Table 13. Global Noninvasive Delivery Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Delivery Vaccine as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Noninvasive Delivery Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Noninvasive Delivery Vaccine Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Noninvasive Delivery Vaccine Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Noninvasive Delivery Vaccine Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Noninvasive Delivery Vaccine Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Noninvasive Delivery Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Noninvasive Delivery Vaccine Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Noninvasive Delivery Vaccine Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Noninvasive Delivery Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Noninvasive Delivery Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Noninvasive Delivery Vaccine Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Noninvasive Delivery Vaccine Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Noninvasive Delivery Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Noninvasive Delivery Vaccine Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Noninvasive Delivery Vaccine Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Noninvasive Delivery Vaccine Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Noninvasive Delivery Vaccine Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Noninvasive Delivery Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Noninvasive Delivery Vaccine Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Noninvasive Delivery Vaccine Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Noninvasive Delivery Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Noninvasive Delivery Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Noninvasive Delivery Vaccine Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Noninvasive Delivery Vaccine Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Noninvasive Delivery Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Noninvasive Delivery Vaccine Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Noninvasive Delivery Vaccine Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Noninvasive Delivery Vaccine Sales Value by Region (2019-2024) & (%)

Table 44. Global Noninvasive Delivery Vaccine Sales Value by Region (2025-2030) & (%)

Table 45. Global Noninvasive Delivery Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Noninvasive Delivery Vaccine Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Noninvasive Delivery Vaccine Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Noninvasive Delivery Vaccine Sales Volume by Region (2019-2024) & (%)

Table 49. Global Noninvasive Delivery Vaccine Sales Volume by Region (2025-2030) & (%)

Table 50. Global Noninvasive Delivery Vaccine Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Noninvasive Delivery Vaccine Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Noninvasive Delivery Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Noninvasive Delivery Vaccine Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Noninvasive Delivery Vaccine Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Noninvasive Delivery Vaccine Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Noninvasive Delivery Vaccine Sales Volume, (2025-2030) & (K Units)

Table 57. Merck Company Information

Table 58. Merck Introduction and Business Overview

Table 59. Merck Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Merck Noninvasive Delivery Vaccine Product Offerings

Table 61. Merck Recent Development

Table 62. GSK Company Information

Table 63. GSK Introduction and Business Overview

Table 64. GSK Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. GSK Noninvasive Delivery Vaccine Product Offerings

Table 66. GSK Recent Development

Table 67. Sanofi Company Information

Table 68. Sanofi Introduction and Business Overview

Table 69. Sanofi Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Sanofi Noninvasive Delivery Vaccine Product Offerings

Table 71. Sanofi Recent Development

Table 72. Lanzhou Institute Company Information

Table 73. Lanzhou Institute Introduction and Business Overview

Table 74. Lanzhou Institute Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Lanzhou Institute Noninvasive Delivery Vaccine Product Offerings

Table 76. Lanzhou Institute Recent Development

Table 77. Serum Institute Company Information

Table 78. Serum Institute Introduction and Business Overview

Table 79. Serum Institute Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Serum Institute Noninvasive Delivery Vaccine Product Offerings

Table 81. Serum Institute Recent Development

Table 82. Valneva Company Information

Table 83. Valneva Introduction and Business Overview

Table 84. Valneva Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Valneva Noninvasive Delivery Vaccine Product Offerings

Table 86. Valneva Recent Development

Table 87. Shanghai United Cell Company Information

Table 88. Shanghai United Cell Introduction and Business Overview

Table 89. Shanghai United Cell Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Shanghai United Cell Noninvasive Delivery Vaccine Product Offerings

Table 91. Shanghai United Cell Recent Development

Table 92. Bibcol Company Information

Table 93. Bibcol Introduction and Business Overview

Table 94. Bibcol Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Bibcol Noninvasive Delivery Vaccine Product Offerings

Table 96. Bibcol Recent Development

Table 97. PaxVax Company Information

Table 98. PaxVax Introduction and Business Overview

Table 99. PaxVax Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. PaxVax Noninvasive Delivery Vaccine Product Offerings

Table 101. PaxVax Recent Development

Table 102. Vabiotech Company Information

Table 103. Vabiotech Introduction and Business Overview

Table 104. Vabiotech Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Vabiotech Noninvasive Delivery Vaccine Product Offerings

Table 106. Vabiotech Recent Development

Table 107. Tiantan Biological Company Information

Table 108. Tiantan Biological Introduction and Business Overview

Table 109. Tiantan Biological Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Tiantan Biological Noninvasive Delivery Vaccine Product Offerings

Table 111. Tiantan Biological Recent Development

Table 112. EuBiologics Company Information

Table 113. EuBiologics Introduction and Business Overview

Table 114. EuBiologics Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. EuBiologics Noninvasive Delivery Vaccine Product Offerings

Table 116. EuBiologics Recent Development

Table 117. Panacea Biotec Ltd Company Information

Table 118. Panacea Biotec Ltd Introduction and Business Overview

Table 119. Panacea Biotec Ltd Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Panacea Biotec Ltd Noninvasive Delivery Vaccine Product Offerings

Table 121. Panacea Biotec Ltd Recent Development

Table 122. Bio-Med Company Information

Table 123. Bio-Med Introduction and Business Overview

Table 124. Bio-Med Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 125. Bio-Med Noninvasive Delivery Vaccine Product Offerings

Table 126. Bio-Med Recent Development

Table 127. Halfkin Bio-Pharmaceuticals Company Information

Table 128. Halfkin Bio-Pharmaceuticals Introduction and Business Overview

Table 129. Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 130. Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Product Offerings

Table 131. Halfkin Bio-Pharmaceuticals Recent Development

Table 132. AstraZeneca Company Information

Table 133. AstraZeneca Introduction and Business Overview

Table 134. AstraZeneca Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 135. AstraZeneca Noninvasive Delivery Vaccine Product Offerings

Table 136. AstraZeneca Recent Development

Table 137. Cipla Company Information

Table 138. Cipla Introduction and Business Overview

Table 139. Cipla Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 140. Cipla Noninvasive Delivery Vaccine Product Offerings

Table 141. Cipla Recent Development

Table 142. BCHT Company Information

Table 143. BCHT Introduction and Business Overview

Table 144. BCHT Noninvasive Delivery Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 145. BCHT Noninvasive Delivery Vaccine Product Offerings

Table 146. BCHT Recent Development

Table 147. Key Raw Materials Lists

Table 148. Raw Materials Key Suppliers Lists

Table 149. Noninvasive Delivery Vaccine Downstream Customers

Table 150. Noninvasive Delivery Vaccine Distributors List

Table 151. Research Programs/Design for This Report

Table 152. Key Data Information from Secondary Sources

Table 153. Key Data Information from Primary Sources

List of Figures

Figure 1. Noninvasive Delivery Vaccine Product Picture

Figure 2. Global Noninvasive Delivery Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Noninvasive Delivery Vaccine Sales Volume (2019-2030) & (K Units)

Figure 5. Global Noninvasive Delivery Vaccine Sales Price (2019-2030) & (US$/Unit)

Figure 6. Noninvasive Delivery Vaccine Report Years Considered

Figure 7. Global Noninvasive Delivery Vaccine Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Noninvasive Delivery Vaccine Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Noninvasive Delivery Vaccine Revenue in 2023

Figure 10. Noninvasive Delivery Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Oral Vaccine Picture

Figure 12. Nasal Spray Vaccine Picture

Figure 13. Global Noninvasive Delivery Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Noninvasive Delivery Vaccine Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Noninvasive Delivery Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Noninvasive Delivery Vaccine Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Noninvasive Delivery Vaccine Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Public

Figure 19. Product Picture of Private

Figure 20. Global Noninvasive Delivery Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Noninvasive Delivery Vaccine Sales Value Market Share by Application, 2023 & 2030

Figure 22. Global Noninvasive Delivery Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 23. Global Noninvasive Delivery Vaccine Sales Volume Market Share by Application, 2023 & 2030

Figure 24. Global Noninvasive Delivery Vaccine Price by Application (2019-2030) & (US$/Unit)

Figure 25. North America Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 26. North America Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 27. Europe Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 28. Europe Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 29. Asia Pacific Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 30. Asia Pacific Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 31. South America Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 32. South America Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 33. Middle East & Africa Noninvasive Delivery Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 34. Middle East & Africa Noninvasive Delivery Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 35. Key Countries/Regions Noninvasive Delivery Vaccine Sales Value (%), (2019-2030)

Figure 36. Key Countries/Regions Noninvasive Delivery Vaccine Sales Volume (%), (2019-2030)

Figure 37. United States Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 38. United States Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 39. United States Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 40. Europe Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 41. Europe Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 42. Europe Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 43. China Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 44. China Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 45. China Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 46. Japan Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 47. Japan Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 48. Japan Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 49. South Korea Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 50. South Korea Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 51. South Korea Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 52. Southeast Asia Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 53. Southeast Asia Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 54. Southeast Asia Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 55. India Noninvasive Delivery Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 56. India Noninvasive Delivery Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 57. India Noninvasive Delivery Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 58. Noninvasive Delivery Vaccine Industrial Chain

Figure 59. Noninvasive Delivery Vaccine Manufacturing Cost Structure

Figure 60. Channels of Distribution (Direct Sales, and Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions